Phase 1/2 study with our HDAC inhibitor mocetinostat in combination with MedImmune’s PD-L1 inhibitor MEDI4736 in patients with Advanced Solid Tumors and NSCLC

Sponsor
Mirati Therapeutics

Protocol Number
Mirati 0103-020

To Learn More Call
201-510-0910